



ITCQ

**Conformity Assessment
of IVDs
(98/79/EC)**

Contents of the Presentation



- ❖ **Overview of the EU Directive on IVD medical devices**
 - Key features of the Directive
 - Technical Documentation
 - Classification of IVD devices
 - Registration
 - Conformity Assessment Procedures
- ❖ **Design Dossier Evaluation**
 - Performance Evaluation
- ❖ **Audits**
- ❖ **Laboratory Testing of Devices for Batch Verification**
- ❖ **Obligations of the Manufacturer to the Notified Body**
- ❖ **Harmonized Standards**

The European directive on IVD



- **Directive 98/79/EC of 27 October 1998 on IN VITRO DIAGNOSTIC MEDICAL DEVICES ("IVDDs")**

...came into full effect on December, 2003

- ✓ placing on the market
- ✓ putting into service
- ✓ use of IVDs
- ✓ post market surveillance

supported by

- **COMMISSION DECISION (2002/364/EC) of 7 May 2002 on COMMON TECHNICAL SPECIFICATIONS for *in vitro*-diagnostic medical devices ("CTS")**
- Harmonized Standards

Key Features of IVDD (I)



- All devices to be marketed in Europe have to successfully pass a Conformity Assessment acc. to the respective Directive
- Compliance to European Requirements is indicated by the CE mark on the product
- It is the **manufacturer's responsibility** to ensure conformity
- Devices must comply with **Essential Requirements (Ax I)**
- Conformity may be achieved by meeting the requirements of **Harmonized Standards**
- Performance and quality control testing must meet **CTS** whenever these are available for a product
- Compliance must be evident in the **Technical Documentation**
- Depending on the **risk** associated with the intended use of an individual device, the device is **classified**. The class of a device defines the available options/routes for **Conformity Assessment**

Key Features of IVDD (II)



- Devices of higher risk class require participation of a **Notified Body** in conformity assessment
- The manufacturer can **select** the conformity assessment route and Notified Body, if options are available
- Manufacturers outside the EU must have a **Representative in the EU**
- The manufacturer respectively his European Representative has to **register** the products at the Competent Authority of his EU member state
- Incidents, near incidents, and recalls have to be **reported** to Competent Authorities (Vigilance)
- Beside legislation **Competent Authorities** are responsible for registration, market surveillance, and designation and monitoring of Notified Bodies

Technical Documentation (IVDD Annex III, IV, and V)



= **Basis for every conformity assessment**

Central elements:

- ✓ Device description (incl. intended use, legal manufacturer, manufacturing sites)
- ✓ Prove of compliance to Essential Requirements (ER Checklist + data) incl. references to harmonized standards applied and CTS if applicable
- ✓ Risk / Benefit assessment of the manufacturer
- ✓ Qualification / performance evaluation data / stability data
- ✓ Instruction for Use / Labeling
- ✓ Description of the manufacturing process incl. QC activities
- ✓ Material-, manufacturing-, and release specifications
- ✓ Declaration of Conformity
- **see NB-MED/2.5.1/Rec 5 for details regarding compilation**

Classification acc. to IVDD (I)



IVD is each medical product that is

- reagent
- reactive product
- calibration material
- control material
- kit
- instrument
- device, or a system

and that shall be used for the in vitro investigation of specimens originating from the human body (*saliva, perspiration, excrements, blood, tissue samples*), to provide information

- concerning a physiological or pathological state
- concerning a congenital (inherited) abnormality
- to determine the safety and compatibility with potential recipients
- to monitor therapeutic processes

Specimen receptacles (for in-vitro samples storage) are IVDs.

Classification acc. to IVDD (II)



In-Vitro Directive relates to medical devices for in vitro diagnostics and their accessories.

Excluded are:

- products for general laboratory use, provided that the manufacturer did not appointed those products as specialised for in-vitro testing
- invasive sampling devices for collecting samples for in-vitro diagnostic
- IVD devices produced and used in the same institution, without any transport or sale to other bodies

Classification acc. to IVDD (III)



The directive recognises **four categories of IVD** depending on the risk which they present to the user:

- ✓ General IVDs
- ✓ IVDs for self-testing, i.e. test kits used in a home environment (excluding self test devices covered by Annex II)
- ✓ IVDs in Annex II, List B of the Directive, e.g. test kits for Rubella, Chlamydia, CMV, PSA, or the major tissue typing groups
- ✓ IVDs in Annex II List A of the Directive, e.g. test kits for HIV, hepatitis B, C, or D, HTLV and the major blood groups

Classification acc. to IVDD (IV)



- Classification of IVD products is performed acc. to **List A** and **B** of **Annex II** of the Directive and used for **self-testing**
- Criteria for listing devices in list A and list B are associated with:
 - risk in blood transfusion / transplantation
 - prevention of AIDS and certain types of hepatitis
 - protection for newborns
 - minimizing long term damages due to certain illnesses
- **All devices listed in Annex II and intended for self-testing** require participation of a Notified Body in Conformity Assessment
- **All other IVD products do not require** a Conformity Assessment under participation of a Notified Body

Annex II, list A of IVDD



- reagents, related calibrators and control materials, for determining the following blood groups:
 - ABO system
 - rhesus system (C, c, D, E, e)
 - anti-Kell

- reagents, related calibrators and control materials, for the detection, confirmation and quantification in human specimens of markers of
 - HIV infection (HIV 1 & 2) Human Immunodeficiency Virus
 - HTLV I and II (Human T-cell Lymphotropic Virus)
 - and hepatitis B, C and D

Blood grouping products covered by Annex II



Products:

Reagents, reagent products, calibrators, and controls for determination

List A:

- ABO-System
- Rhesus (C, c, D, E, e)
- anti-Kell

List B:

- anti-Duffy
- anti-Kidd
- irregular anti-erythrocyte antibodies

Blood grouping products NOT covered by Annex II



IVDs for self-testing:

- none

Other IVD products:

- other blood group systems / antigens (N, M, S, Le, C^{wk}, etc.)
- sample containers / stabilization / transport systems
- sample preparation systems, i.e. nucleic acid extraction systems
- specific instruments and software

Annex II, list B of IVDD



- IVD for determining the following blood groups: anti-Duffy & anti-Kidd
- IVD for determining irregular anti-erythrocytic antibodies
- IVD for the detection of the congenital infections: rubella, toxoplasmosis
- IVD for diagnosing of phenylketonuria
- IVD for determining infections by cytomegalovirus, chlamydia
- IVD for determining the HLA tissue groups: DR, A, B
- IVD for detection tumoral marker: PSA
- IVD for evaluating the risk of trisomy 21
- IVD for self-diagnosis of blood sugar content

Registration (IVDD Art. 10)



at the Competent Authorities of the Member State of his registered place of business (of authorized representative)

and – *as long as no European databank is available* – to the competent authorities of all member states where the product is placed on the market:

- Address of registered place of business
- Information on the products (indications, characteristics), significant changes, discontinuation
- For Annex II and self-testing devices data allowing identification, label, IFU, and certificates of Notified Body and any change thereto
- For Annex II and self-testing devices member states may request data allowing identification, label, and IFU when products are placed on their markets
- New products have to be indicated when registered

Vigilance Procedure in IVDs



- IVD products are as well as other medical devices a subject of vigilance procedure (the essential requirement of the administrative type)
- The **manufacturer shall have a procedure** for post market surveillance and reporting of adverse incidents.
- The **documentation system should be established**, where any positive, but especially negative information from users, physicians and another person or bodies are collected and archived.
- Acquired information shall the manufacturer immediately send to national authority, responsible for the vigilance

Prerequisites for Conformity



- 1) **Adequate Design** of a Device
- 2) **Consistent Reproduction** of the Device as designed
- 3) **Adequate Verification** of the Quality of the Device

Conformity assessment procedures IVDD




Modules used:

- Design Evaluation
 - Design Examination (Annex IV.4) – Document Review
 - Type Examination (Annex V) – Prototype Testing
 - Design Examination (Annex III.6) – Document review

- Assessment of Implementation of Quality Management System Requirements (initial and annual recurring)
 - with Design Process incl. Technical File Review (Annex IV.3)
 - without Design Process (Annex VII.3)

- Testing of Manufactured Products
 - EC Verification (Annex VI)
 - Batch Verification (Annex IV.6 & VII.5)

Conformity assessment procedures IVDD



Registration Number of Notified Body
e.g. 1023 for ITC, Inc, Zlin

- * LA- Ax II, List A devices
- LB- Ax II, List B devices
- ST- Self-testing devices

Responsibility of Manufacturer

Responsibility of Notified Body

Conformity assessment procedures IVDD



For **List A devices**, Manufacturers can choose between two routes:

Route 1 – Full Quality Assurance System

consisting of

- Design Dossier review (IV.4) = **Document Review**
- Certification & Surveillance Audits (IV.3 / IV.5)
- Verification of every batch (IV.6)

OR

Route 2 – EC Type-Examination + Production Quality Assurance

consisting of

- EC Type-Examination/Testing (V) = **Physical Testing**
- Certification & Surveillance Audits (VII.3 / VII.4)
- Verification of every batch (VII.5)

Conformity assessment procedures IVDD



For **List B devices**, a third is possible (optional to Route 1 or 2):

Route 3 – EC Type Testing + EC Verification

consisting of

- EC Type-Examination (V) = **Physical Testing**
- EC Verification (VI) = **Physical Testing** of every device or via strategic sampling

For **Self-testing devices**, another route is possible (optional to Route 1 to 3):

Route 4 – Design Examination (III.6) = Documentation Review

Design Dossier / Technical File Evaluation



- ✓ intended use
- ✓ specifications
- ✓ ER Checklist with reference to utilized harmonized standards
- ✓ risk analysis
- ✓ chemical & biological safety
- ✓ suitability of packing
- ✓ qualification / **performance evaluation** data of the device
- ✓ stability data
- ✓ labeling, instruction for use
- ✓ manufacturing process
- ✓ QC-testing regimen and acceptance criteria
- ✓ draft of Declaration of Conformity

Performance Evaluation acc. to IVDD



Performance evaluation data

- ✓ are necessary for **all** devices
- ✓ performance data should originate from studies in clinical or other appropriate environment and / or results from relevant biographical references
- ✓ performance to be shown in comparison with CE marked reference tests
- ✓ Annex VIII of IVDD describes requirements for devices to be used in performance evaluation and respective procedure
- ✓ Art. 5 establishes the requirement for Annex II List A devices to meet **Common Technical Specifications**:
 - performance evaluation and re-evaluation criteria
 - batch release criteria
 - reference methods & reference materials

The CTS Structure



1. Scope
2. Definitions
3. Common Technical Specifications (CTS) for products defined in Ax II List A
 - 3.1 CTS for performance evaluation of reagents & reagent products for the detection, confirmation and quantification in human specimens of markers of HIV infection (HIV 1 & 2), HTLV I and II, and hep B, C, D. General Principles
 - 3.2 Additional requirements for Nucleic Acid Amplification Techniques (NAT)
 - 3.3 CTS for the manufacturer's release testing of reagents and reagent products for the detection, confirmation and quantification in human specimens of markers of HIV infection (HIV 1 & 2), HTLV I & II, and hepatitis B, C, D (Immunological assays only)
 - 3.4 CTS for performance evaluation of reagents & reagent products for determining the blood group antigens: ABO system (A,B), rhesus (C, c, D, E, e) and Kell
 - 3.5 CTS for the manufacturer's release testing of reagents and reagent products for determining the blood group antigens: ABO system (A,B), rhesus (C, c, D, E, e) and Kell

The CTS - Tables



Table 1: "Screening" assays: anti HIV 1 & 2, anti HTLV I & II, anti HCV, HBsAg, anti HbC"

Table 2: Nucleic acid amplification techniques (NAT) for HIV 1, HCV, HBV, HTLV I & II (qualitative and quantitative tests)

Table 3: Rapid tests: anti HIV 1 & 2, anti HCV, HBsAg, anti HbC, anti HTLV I & II

Table 4: Confirmatory / supplementary assays for anti HIV 1 & 2, anti HTLV I & II, anti HCV, HbsAg

Table 5: HIV1 antigen

Table 6: Serotyping assay: HCV

Table 7: HBV markers: anti HBs, anti HBcIgM, anti HBe, HBeAg

Table 8: HDV markers: anti HDV, anti HDV IgM, Delta Antigen

Table 9: Blood Groups ABO, rhesus (C,c,D,E,e), and Kell

Table 10: Batch release criteria for Blood Groups ABO, rhesus (C,c,D,E,e), and Kell

Items / Function inspected during audits



EN ISO 13485:2003 applies for IVD

- QM-Documentation
- Management Responsibility
- Design process
 - Performance Evaluations
 - Change Control
- Technical Documentation
- Production
 - Instructions, Records, Conditions, Traceability
 - Packaging, Labeling
 - Process validation, Equipment Validation, Software Validation
- Storage, Transport
- Quality Control
- Maintenance, Calibration
- Human Resources, Training
- Purchasing, Supplier Contracts
- Marketing activities
- Customer Service
 - Complaint Handling
- Regulatory Affairs
 - Classification of products
 - Vigilance system / issues
- Quality Assurance
 - CAPAs
 - Internal Audits

Batch Verification of IVDs (List A)



Objective and Measures

- Ensuring of batch to batch consistency by monitoring
- Consideration of test results obtained by manufacturer and independent test laboratory
- Values obtained must be within a predefined range

Generally accepted test results from:

- IVD –Testing Laboratory at Paul-Ehrlich-Institut (PEI), Langen

Obligations of the Manufacturers



The manufacturer has the following obligations to NB:

- Notification of all significant changes in the quality management system, production technology and product portfolio
- Notification of all significant changes to the design and manufacture of Annex II List A products
- Notification of all reportable incidents or near incidents for products under the scope of the EC certificate
- For Annex II List A products: Provision of all batches for verification of manufactured product before release to market
- To allow annual audits and - in case of problems - ad hoc audits by the Notified Body at related facilities.

Important Harmonized Standards for IVD (I)



For a current list of harmonized standards see:

<http://ec.europa.eu/enterprise/newapproach/standardization/harmstds/reflist/invimedd.html>

Selected Standards

- **EN 375:2001** *Information supplied by the manufacturer with in vitro diagnostic reagents for professional use*
- **EN 980/A2:2001** *Graphical symbols for use in the labeling of medical devices*
- **EN 12286:2000** *In vitro diagnostic medical devices -Measurement of quantities in samples of biological origin -Presentation of reference measurement procedures*
- **EN 12287:1999** *In vitro diagnostic medical devices - Measurement of quantities in samples of biological origin - Description of reference materials*

Important Harmonized Standards for IVD (II)



- EN 13612:2002 *Performance evaluation of in vitro diagnostic medical devices*
- EN 13640:2002 *Stability testing of in vitro diagnostic medical devices*
- EN 13641:2002 *Elimination or reduction of risk of infection related to in vitro diagnostic medical devices*
- EN 13975:2003 *Sampling procedures used for acceptance testing of in vitro diagnostic medical devices. Statistical aspects*
- EN ISO 14971:2000 *Medical devices -Application of risk management to medical devices*
- EN ISO 17511:2003 *In vitro diagnostic medical devices - Measurements of quantities in samples of biological origin - Metrological traceability of values assigned to calibrators and control materials*

Important Harmonized Standards for IVD (III)



- EN 591:2001 *Instructions for use for in vitro diagnostic instruments for professional use*
- EN 61010-2-101:2002 *Safety requirements for electrical equipment for measurement, control and laboratory use -Particular requirements for in vitro diagnostic (IVD) medical equipment (General requirements see EN 61010-1 : 2001)*



Thank you for attention

Jan Petrik, PhD.
Institute for Testing and Certification, Inc. Zlín
Branch Office ITC Slovakia,
Mlynske Nivy 54
SK-821 05 Bratislava
SLOVAK REPUBLIC

jpetrik@itczlin.cz

www.itczlin.cz

phone +421 2 5342 1046

fax +421 2 5342 1032